Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 6/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL586771 | 0.91 | SIGMAR1 (0.43) | SMN1; SMN2NPC1RAB9ASIGMAR1TMEM97 | |
| SCHEMBL2996181 | 0.88 | TMEM97 (0.51) | SIGMAR1TMEM97ACE2 | |
| SCHEMBL2996185 | 0.88 | TMEM97 (0.51) | SIGMAR1TMEM97ACE2 | |
| SCHEMBL582341 | 0.87 | SIGMAR1 (0.45) | SIGMAR1TMEM97 | |
| SCHEMBL586903 | 0.82 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9ASIGMAR1TMEM97 | |
| SCHEMBL28565328 | 0.81 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9ASIGMAR1TMEM97 | |
| SCHEMBL582233 | 0.80 | SIGMAR1 (0.47) | SIGMAR1TMEM97 | |
| SCHEMBL29284593 | 0.77 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL29284592 | 0.77 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL15017542 | 0.77 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415378-B2 | Isoxazol-3(2H)-one analogs as therapeutic agents | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | disclosed |
| EP-2417131-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010117323-A1 | METHOD AND APPARATUS FOR PRODUCING HEAT ENERGY AND CARBON DIOXIDE | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261755-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261755-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | NR4A3, CBR3, OXER1 | SMN1; SMN2 2619/4885NPC1 497/4885RAB9A 3760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.